title: [Annexin V levels in survivors of early myocardial infarction].
abstract: OBJECTIVE
  Annexin V has an anticoagulant effect in vitro that derives from its ability to displace coagulation proteins from phospholipid surfaces, prolonging phospholipid-dependent coagulation reactions. Antiphospholipid antibodies (APL) and annexin V have an affinity for anionic phospholipids, so it has been hypothesized that one of the thrombotic mechanisms of APL may be due to displacement of annexin V from phospholipid surfaces. We studied plasma annexin V levels and analyzed its relationship to risk factors and several blood markers.
  
  
  METHODS
  We studied 62 patients < 45 years old who had suffered myocardial infarction. The control group comprised 23 healthy subjects of similar age and sex. We analyzed the presence of APL, anti-beta2 glycoprotein I (beta2-GPI), anti-beta2-GPI/phospholipid complexes and anti-annexin V antibodies. We determined plasma annexin V levels. Cholesterol, HDL-cholesterol, triglycerides, antigenic tissue plasminogen activator and its inhibitor, von Willebrand factor, and fibrinogen levels were measured.
  
  
  RESULTS
  We detected only 2 patients with positive anti-beta2-GPI/phospholipid complexes and 2 patients with positive anti-annexin V antibodies. We did not detect any positive APL or anti-beta2-GPI antibodies. In the control group there was only 1 patient with positive APL and anti-beta2-GPI antibodies. The myocardial infarction group showed significantly lower levels of annexin V than the control group: 0.640 ng/ml (0.520-0.818 ng/ml) vs 1.570 ng/ml (1.140-2.390 ng/ml), p < 0.01. There were no statistical associations between annexin V levels and other variables.
  
  
  CONCLUSIONS
  The low levels of annexin V in young myocardial infarction patients could indicate a procoagulant trend. This hypercoagulable state was unrelated to the presence of APL.
authors.affiliation: Unidad de Hematología. Hospital de San Vicente. Alicante. Spain.
authors.forename: Vanessa
authors.initials: V
authors.lastname: Roldán
authors.forename: Francisco
authors.initials: F
authors.lastname: Marín
authors.forename: Javier
authors.initials: J
authors.lastname: Pineda
authors.forename: Pascual
authors.initials: P
authors.lastname: Marco
authors.forename: Javier
authors.initials: J
authors.lastname: Corral
authors.forename: Vicente
authors.initials: V
authors.lastname: Climent
authors.forename: Amaya
authors.initials: A
authors.lastname: García
authors.forename: Juan G
authors.initials: JG
authors.lastname: Martínez
authors.forename: Francisco
authors.initials: F
authors.lastname: Sogorb
mesh_terms: D000328:Adult; D017304:Annexin A5 / Q000097:blood*; D017152:Antibodies, Antiphospholipid / Q000097:blood; D001780:Blood Coagulation Tests; D004791:Enzyme Inhibitors / Q000097:blood*; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000175:diagnosis / Q000401:mortality; D017741:Survivors
chemical_list: D017304:Annexin A5; D017152:Antibodies, Antiphospholipid; D004791:Enzyme Inhibitors; D008055:Lipids